Table 2 Results of the stratified meta-analyses for operative time.
Variable | Trials (no.) | ES | 95% CI | Tau^3 | I^2 (modified) | |
|---|---|---|---|---|---|---|
All trials | 12 | − 9.4 | − 19.98 | 1.18 | 311.9(*) | |
Intervention | 280.8 | |||||
PFN | 6 | − 2.4 | − 16.32 | 11.52 | 90% | 88% |
PFNA | 5 | − 17.7 | − 32.6 | − 2.8 | ||
Fracture pattern | 383.1 | |||||
Stable | 4 | − 6.2 | − 28.94 | 16.54 | 123% | 120% |
Unstable | 5 | − 900 | − 26.44 | 8.44 | ||
Mix | 3 | − 13.1 | − 35.44 | 9.24 | ||
Follow-up | 372.4 | |||||
Short | 2 | − 1.5 | − 28.55 | 25.55 | 119% | 117% |
Intermediate | 8 | − 11,00 | − 24.72 | 2.72 | ||
Long | 2 | − 12.8 | − 52,00 | 26.4 | ||
Country | 532.14 | |||||
China | 4 | − 20,00 | − 46.26 | 6.26 | 171% | 167% |
Finland | 1 | 10,00 | − 35.86 | 55.86 | ||
Greece | 1 | 12,00 | − 35.63 | 59.63 | ||
India | 2 | − 14.6 | − 47.33 | 18.13 | ||
Pakistan | 1 | − 23.4 | − 68.68 | 21.88 | ||
Switzerland | 1 | − 100 | − 46.86 | 44.86 | ||
Turkey | 1 | − 12.5 | − 57.78 | 32.78 | ||
UK | 1 | 300 | − 42.28 | 48.28 | ||
Random sequence generation | 293.4 | |||||
Low | 10 | − 7.3 | − 18.28 | 3.68 | 94% | 92% |
High | 0 | |||||
Unclear | 2 | − 30.7 | − 64.8 | 3.4 | ||
Allocation concealment | 256 | |||||
Low | 5 | − 0.6 | − 14.91 | 13.71 | 82% | 80% |
High | 0 | |||||
Unclear | 7 | − 17.1 | − 30.43 | − 3.77 | ||
Blinding of outcome assessment | 344.5 | |||||
Low | 2 | − 13.6 | − 39.47 | 12.27 | 110% | 108% |
High | 0 | |||||
Unclear | 10 | − 8.4 | − 20.75 | 3.95 | ||
Incomplete outcome data | 311.9 | |||||
Low | 12 | − 9.42 | − 20,00 | 1.16 | 100% | 98% |
High | 0 | |||||
Unclear | 0 | |||||
Selective reporting | 311.9 | |||||
Low | 12 | − 9.42 | − 20,00 | 1.16 | 100% | 98% |
High | 0 | |||||
Unclear | 0 | |||||